Celcuity Inc. (CELC) Stock

Understand Celcuity Inc.: how it makes money

Celcuity is a clinical-stage biotech developing Gedatolisib, a targeted PI3K/mTOR inhibitor for advanced breast cancer, paired with its CELsignia tumor-classification diagnostic. It is pre-revenue with a single Phase 3 asset, so the investment case is entirely a clinical-outcome bet funded by equity raises.

All future profitability depends on one binary event: Gedatolisib Phase 3 data clearing FDA review. Until that happens, the company converts investor capital into clinical milestones and has no other revenue source.

Business quality (Unprofitable): Unprofitable. No product revenue, a deeply negative operating margin of -1592%, and a cash runway that ends in 2027 make this a pure optionality play on a single trial readout.

Bull case

• Multi-billion peak revenue estimate: Management estimates potential second-line peak revenue of up to $2.5 billion annually, which if realized would place Gedatolisib among the largest single-agent breast cancer treatments on the market.
• Broad patient applicability across cohorts: Both PIK3CA cohorts (mutated and wild-type) support potential second-line use regardless of mutation status, meaning the eligible patient pool is not limited to a genetic subset and the label could cover the full HR-positive, HER2-negative population.
• First-line market adds 90,000 patients: First-line expansion targets approximately 90,000 newly diagnosed U.S. women annually, a large addressable market that would extend the drug's life well beyond the current second-line indication.

Bear case

• Cash runway ends in 2027: Quarterly net cash use rose to $55.1 million, and management's current financing plan funds operations only through 2027, leaving a narrow window before another dilutive capital raise is required.
• Key data not until 2030: First-line endocrine-sensitive trial data are not expected until 2030, meaning investors must commit capital for several more years before learning whether the largest expansion indication actually works.
• Formulation adds years of complexity: Subcutaneous development requires pharmacokinetic studies and likely a bioequivalence study, adding cost and timeline to a formulation that improves convenience but is not needed for the IV label.

Related Companies (Healthcare Services; 8 comparable companies)

• American Shared Hospital Services (AMS)
• Exagen Inc. (XGN)
• Personalis, Inc. (PSNL)
• Biodesix, Inc. (BDSX)
• GRAIL, Inc. (GRAL)
• BillionToOne, Inc. (BLLN)
• Basel Medical Group Ltd Ordinary Shares (BMGL)
• Fulgent Genetics, Inc. (FLGT)